Students Earn While They Learn

Many home economics women are earning as well as learning at Iowa State with some of them receiving financial aid and gaining practical experience at the same time

The Iowa Homemaker vol.23, no.14

Winter in Iowa, page 2 Keeping Up With Today, Mary Elizabeth Lush, page 2 Presenting Martha Duncan, D. Jean Merrill, page 3 Students Create Furniture, Marjorie Lund, page 4 Describe Food in South Pacific, Gertrud Ortgies, page 5 Vicky Previews a New Year, Josephine Ahern, page 6 Teaches Homemaking in India, Mrs. Edgar Vestal, page 7 What’s New in Home Economics, Marilyn Mitchell, page 8 Thoughtful Reading, Jo Ann Reeves, page 10 Across Alumnae Desks, Harriet Keen, page 12 Alum Chooses Food Publicity, Rowena Lincoln, page 14 Betty Heileman Feeds Trainees, Ann Turner, page 1

The Iowa Homemaker vol.23, no.15

Keeping Up With Today, D. Jean Merrill, page 2 Institution Recipes Are Acclaimed, Victoria McKibben, page 3 Democracy Begins in the Home, Jean Larson, page 4 Schools Sponsor Nutrition Program, Jean Bunge, page 5 Vicky Rehearses for Spring, Josephine Ahern, page 6 What’s New in Home Economics, Marilyn Mitchell, page 8 Benefit from College Placement, Mary Elva Sather, page 10 Well-known Cooks Open Their Kitchens, Mary E. Lush, page 11 Alums in the News, Patricia Maddex, page 12 Distinguished Alumnus Credits Home, Marjorie Shuler, page 14 Across Alumnae Desks, Harriet Keen, page 15 Women’s Follies in Fashion, Lila Mae Hummel, page 1

The Iowa Homemaker vol.21, no.9

Keeping Up With Today, Marilyn Clayton, page 2 Need for Homemaking Education, Lois Stewart, page 3 Uniforms Alter Campus Co-Etiquette, Joan Miller, page 5 Keynotes Furnishings, Interview, Misses Fisher, O’Bryan, page 6 For a Vacation With Pay, Pat O’Connell, page 8 A Graduate Describes Food Publicity, Winnifred Cannon, page 9 Shipyards Sponsor Child Care Centers, Jeanne O’Connor, page 10 Silhouette for Spring, Ruth Midgorden, page 11 What’s New in Home Economics, Mildred Krogh, page 12 Iowa State Promotes Gardens for Victory, Jo Ann Reeves, page 14 Do You Manage Your Time Efficiently?, Marian Loofe, page 15 Dietitians to the Front, Lorraine Berger, page 16 Across Alumnae Desks, Harriet Keen, page 18 Notions Corner, page 20 Efficiency in Food Preparation, Norma Dale, page 21 Alums in the News, Patricia Maddex, page 2

The Iowa Homemaker vol.23, no.13

Winter in Iowa, page 2 Keeping Up With Today, D. Jean Merrill, page 3 “We’re in The Army Now”, Jeannette Pickford, page 4 Decorate For Christmas Festivities, June Hudek, page 5 Make Your Christmas Gifts, Marian Hoppe, page 6 Public Relations To The Fore, Dorothy Ann Roost, page 7 Vicky Fashions Her Christmas, Josephine Ahern, page 8 Occupational Therapists, Gertrud Ortgies, page 10 Dress Up Your Christmas Packages, Rosalie Riglin, page 11 Express Yourself To Impress Others, Doris Ann Gregg, page 12 Their Diets Are Supervised, Eugenia Crawford, page 13 What’s New In Home Economics, Marilyn Mitchell, page 14 Across Alumnae Desks, Harriet Keen, page 18 He Cooked In The Clouds¸ Dick Crowther, page 20 Plans For Her Country’s Future, Thelma Estevez, page 22 Foods of the Future, Shirley Rolfs, page 24 Yuletide Celebrations In Other Lands, Mary Rothacker, page 26 Alums In The News, Patricia Maddex, page 2

The Iowa Homemaker vol.23, no.10

Keeping Up With Today, Marilyn Clayton, page 2 Victory Canning Corps, Corinne Cunningham, page 3 Posters for South America, Frances Kerekes, page 4 Choosing Your College, Clara M. Brown, page 5 For Random Reading, Lila Mae Hummel, page 7 Wanted: More Home Economics, Victoria McKibben, page 9 Teaching Field Broadens in Scope, Norma Shellito, page 10 Food Customs from the Phillipines, Soledad Payawal, page 11 Sheer Simplicity, Josephine Ahern, page 12 Association Benefits Graduates, Zoe Wilson, page 14 Forecasting Textile Supply, Elizabeth Peterson, page 15 What’s New in Home Economics, Mildred Krogh, page 16 Packaging for Post War Foods, Virginia Carter, page 18 Challenge from Latin America, Delores Stewart, page 19 Designed for Individuality, Gertrude Richards, page 21 More Products from Plastics, Mary Elizabeth Lush, page 23 Fashions in Weeds, Marilyn Baker, page 24 Across Alumnae Desks, Harriet Keen, page 26 Rehabilitation Challenges Home Economist, Marian Hoppe, page 28 Alums in the News, Patricia Maddex, page 30 Electronics Change Food Flavors, Barbara Reader, page 3

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence. The ability to track the evolutionary dynamics of early-stage lung cancer non-invasively in circulating tumour DNA (ctDNA) has not yet been demonstrated. Here we use a tumour-specific phylogenetic approach to profile the ctDNA of the first 100 TRACERx (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy (Rx)) study participants, including one patient who was also recruited to the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent predictors of ctDNA release and analyse the tumour-volume detection limit. Through blinded profiling of postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients who are very likely to experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastasis, providing a new approach for ctDNA-driven therapeutic studies

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials